Published by Coherent Market Insights
Posted on October 6, 2021
4 min readLast updated: January 30, 2026
The Human Microbiome Market is set to grow to $306 billion by 2028, with a CAGR of 18.9%. North America leads due to high IBD prevalence.
The Human Microbiome Market report presents the industry sales and revenue by companies, regions, type and application and forecast to 2028. This report also studies the market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/182
The human microbiota (the various microbial communities constantly living in the body) is now one of the largest researched areas in clinical biology. There are many interesting areas of study in this field, all of which have great importance to helping us understand and ultimately control some of the common diseases that plague our society today such as diabetes, obesity, heart disease, and more. The human intestinal tract is home to several hundred thousand microbial species. Together these bacteria form a community that is tightly connected to the immune system of the body and very closely associates with the DNA of each patient. The study of the human microbiota aid in the prevention of Crohn’s disease and ulcerative colitis condition.
Market Drivers:
Growing research & development activities by key players in order to get a better understanding of microbes on human health is augmenting growth of the Human Microbiome Market. For instance, in November 2019, Nestlé has entered into a partnership with the University of California San Diego Center for Microbiome Innovation (CMI) to increase the understanding of the microbiome’s impact on human health and to accelerate the development of innovative nutritional solutions.
The increasing focus of key manufacturers to launch new and innovative medical food products is uplifting growth of the market. For instance, in June 2019, Shoreline Biome, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, has launched the first end-to-end sample prep kit on the market at the upcoming ASM Microbe 2019 event.
COVID-19 Analysis:
The market of human microbiome market was negatively impacted during the spread of COVID-19 infections. It has severely affected the entire supply chain of the medical food industry due to social distancing norms and lockdown. However, later on, the market has seen positive growth as COVID-19 directly affects the immune system and the use of probiotics improves immunity. This has defiantly raised the demand for probiotics during COVID-19 times.
Key Takeaway:
North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of inflammatory bowel disease in the region. According to the Centers for Disease Control and Prevention’s, Inflammatory Bowel Disease (IBD) in the United States. About 1 percent of the U.S., or 3 million people, live with inflammatory bowel disease (IBD). People are most often diagnosed with Crohn’s disease or ulcerative colitis between ages 15 and 30
The human microbiome market is expected to exhibit a CAGR of XX % over the forecast period, owing to the growing adoption of growth strategies such as mergers &acquasition among key players. For instance, in December 2020, Novozymes has acquired Microbiome Labs. Based in Illinois, US. Microbiome Labs offers a comprehensive portfolio of proprietary probiotic and microbiome solutions and is a vital player in the consumer health industry.
Top Key Players Include In Human Microbiome Market: ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/182
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Human Microbiome Market is expected to grow by US$ 306,351.2 Mn billion by 2028, progressing at a CAGR of 18.9% during the forecast period appeared first on Gatorledger.
The article discusses the growth and future trends of the Human Microbiome Market.
The market is expected to grow to $306 billion by 2028 with a CAGR of 18.9%.
COVID-19 initially impacted the supply chain but later increased the demand for probiotics.
Explore more articles in the Research Reports category
